Skip to main content
. 2021 Oct 26;21(12):1713–1724. doi: 10.1016/S1473-3099(21)00252-8

Figure 1.

Figure 1

Trial profile

In part one, single ascending doses of M5717 (50–2100 mg) were tested in nine cohorts. The volunteer infection study (part two) started after documentation of safety and pharmacokinetics data from the first four cohorts (up to the 400 mg dose cohort) in part one. The volunteer infection study consisted of three dose cohorts (150, 400, and 800 mg).